NC-1059: A channel-forming peptide that modulates drug delivery across in vitro corneal epithelium

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3337-3345

  Martin, Jesica ^a   Malreddy, Pradeep ^a   Iwamoto, Takeo ^a   Freeman, Lisa C ^a   Davidson, Harriet J ^a   Tomich, John M ^a   Schultz, Bruce D ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN; FLUORESCEIN SODIUM; LYSYLLYSYLLYSYLLYSYLALANYLALANYLARGINYLVALYLGLYCYLLEUCYLGLYCYLISOLEUCYLTHREONYLTHREONYLVALYLLEUCYLVALYLTHREONYLTHREONYLISOLEUCYLGLYCYLLEUCYLGLYCYLVALYLARGINYLALANYLALANINE; METHOTREXATE; NC 1059; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; DEXTRAN; DRUG DERIVATIVE; FLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; ION CHANNEL; NC-1059; PEPTIDE; TISSUE SCAFFOLD;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORNEA CELL; CORNEA EPITHELIUM; CORNEA PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENTIATION; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; CELL LINE; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE POTENTIAL; DOSE RESPONSE; DRUG EFFECT; ELECTRIC CONDUCTIVITY; ION TRANSPORT; METABOLISM; TIGHT JUNCTION; TIME; ULTRASTRUCTURE;

CELL LINE, TRANSFORMED; CELL MEMBRANE PERMEABILITY; DEXTRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC CONDUCTIVITY; EPITHELIUM, CORNEAL; FLUORESCEIN; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; ION CHANNELS; ION TRANSPORT; MEMBRANE POTENTIALS; METHOTREXATE; PEPTIDES; TIGHT JUNCTIONS; TIME FACTORS; TISSUE SCAFFOLDS;

EID: 67649986425     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3053     Document Type: Article

References (58)

1. Doane MG, Jensen AD, Dohlman CH. Penetration routes of topically applied eye medications. Am J Ophthalmol. 1978;85:383-386.
2. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Curr Drug Deliv. 2006;3:207-217.
3. Edens HA, Parkos CA. Modulation of epithelial and endothelial paracellular permeability by leukocytes. Adv Drug Deliv Rev. 2000;41:315-328.
4. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol. 2000;279:G851-G857.
5. Woo PL, Cha HH, Singer KL, Firestone GL. Antagonistic regulation of tight junction dynamics by glucocorticoids and transforming growth factor-beta in mouse mammary epithelial cells. J Biol Chem. 1996;271:404-412.
6. Nguyen DA, Parlow AF, Neville MC. Hormonal regulation of tight junction closure in the mouse mammary epithelium during the transition from pregnancy to lactation. J Endocrinol. 2001;170: 347-356.
7. Broughman JR, Brandt RM, Hastings C, Iwamoto T, Tomich JM, Schultz BD. Channel-forming peptide modulates transepithelial electrical conductance and solute permeability. Am J Physiol. 2004;286:C1312-C1323.
8. Somasekharan S, Brandt R, Iwamoto T, Tomich JM, Schultz BD. Epithelial barrier modulation by a channel forming peptide. J Membr Biol. 2008;222:17-30.
9. Reddy GL, Iwamoto T, Tomich JM, Montal M. Synthetic peptides and four-helix bundle proteins as model systems for the poreforming structure of channel proteins. II. Transmembrane segment M2 of the brain glycine receptor is a plausible candidate for the pore-lining structure. J Biol Chem. 1993;268:14608-14615.
10. Broughman JR, Shank LP, Takeguchi W, et al. Distinct structural elements that direct solution aggregation and membrane assembly in the channel-forming peptide M2GlyR. Biochemistry. 2002;41: 7350-7358.
11. Wallace DP, Tomich JM, Iwamoto T, Henderson K, Grantham JJ, Sullivan LP. A synthetic peptide derived from glycine-gated Clchannel induces transepithelial Cl-and fluid secretion. Am J Physiol. 1997;272:C1672-C1679.
12. Becker U, Ehrhardt C, Schneider M, et al. A comparative evaluation of corneal epithelial cell cultures for assessing ocular permeability. Altern Lab Anim. 2008;36:33-44.
13. Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
14. Ryeom SW, Paul D, Goodenough DA. Truncation mutants of the tight junction protein ZO-1 disrupt corneal epithelial cell morphology. Mol Biol Cell. 2000;11:1687-1696.
15. Yi X, Wang Y, Yu FS. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge. Invest Ophthalmol Vis Sci. 2000;41:4093-4100.
16. Filenius S, Tervo T, Virtanen I. Production of fibronectin and tenascin isoforms and their role in the adhesion of human immortalized corneal epithelial cells. Invest Ophthalmol Vis Sci. 2003;44:3317-3325.
17. Xu KP, Yin J, Yu FS. SRC-family tyrosine kinases in wound-and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2006;47: 2832-2839.
18. Xu KP, Yin J, Yu FS. Lysophosphatidic acid promoting corneal epithelial wound healing by transactivation of epidermal growth factor receptor. Invest Ophthalmol Vis Sci. 2007;48:636-643.
19. Huhtala A, Alajuuma P, Burgalassi S, et al. A collaborative evaluation of the cytotoxicity of two surfactants by using the human corneal epithelial cell line and the WST-1 test. J Ocul Pharmacol Ther. 2003;19:11-21.
20. Tomich JM, Wallace D, Henderson K, et al. Aqueous solubilization of transmembrane peptide sequences with retention of membrane insertion and function. Biophys J. 1998;74:256-267.
21. Wang Y, Zhang J, Yi XJ, Yu FS. Activation of ERK1/2 MAP kinase pathway induces tight junction disruption in human corneal epithelial cells. Exp Eye Res. 2004;78:125-136.
22. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004;32:180-184.
23. Lemp MA, Zimmerman LE. Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am J Ophthalmol. 1988;105:670-673.
24. Kahn CR, Young E, Lee IH, Rhim JS. Human corneal epithelial primary cultures and cell lines with extended life span: in vitro model for ocular studies. Invest Ophthalmol Vis Sci. 1993;34: 3429-3441.
25. Mohan RR, Possin DE, Sinha S, Wilson SE. Development of genetically engineered tet HPV16-E6/E7 transduced human corneal epithelial clones having tight regulation of proliferation and normal differentiation. Exp Eye Res. 2003;77:395-407.
26. Offord EA, Sharif NA, Mace K, et al. Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies. Invest Ophthalmol Vis Sci. 1999;40:1091-1101.
27. Griffith M, Osborne R, Munger R, et al. Functional human corneal equivalents constructed from cell lines. Science. 1999;286:2169-2172.
28. Reichl S, Bednarz J, Muller-Goymann CC. Human corneal equivalent as cell culture model for in vitro drug permeation studies. Br J Ophthalmol. 2004;88:560-565.
29. Zorn-Kruppa M, Tykhonova S, Belge G, Bednarz J, Diehl HA, Engelke M. A human corneal equivalent constructed from SV40-immortalised corneal cell lines. Altern Lab Anim. 2005;33:37-45.
30. Klyce SD, Neufeld AH, Zadunaisky JA. The activation of chloride transport by epinephrine and Db cyclic-AMP in the cornea of the rabbit. Invest Ophthalmol. 1973;12:127-139.
31. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007;30: 2360-2364.
32. Ranta VP, Laavola M, Toropainen E, Vellonen KS, Talvitie A, Urtti A. Ocular pharmacokinetic modeling using corneal absorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells. Pharm Res. 2003;20:1409-1416.
33. Toropainen E, Ranta VP, Talvitie A, Suhonen P, Urtti A. Culture model of human corneal epithelium for prediction of ocular drug absorption. Invest Ophthalmol Vis Sci. 2001;42:2942-2948.
34. Toropainen E, Ranta VP, Vellonen KS, et al. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. Eur J Pharm Sci. 2003;20:99-106.
35. Klyce SD, Crosson CE. Transport processes across the rabbit corneal epithelium: a review. Curr Eye Res. 1985;4:323-331.
36. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269:1-14.
37. Marsh RJ, Maurice DM. The influence of non-ionic detergents and other surfactants on human corneal permeability. Exp Eye Res. 1971;11:43-48.
38. Green K, Tonjum A. Influence of various agents on corneal permeability. Am J Ophthalmol. 1971;72:897-905.
39. Morimoto K, Nakai T, Morisaka K. Evaluation of permeability enhancement of hydrophilic compounds and macromolecular compounds by bile salts through rabbit corneas in-vitro. J Pharm Pharmacol. 1987;39:124-126.
40. Sasaki H, Nagano T, Yamamura K, Nishida K, Nakamura J. Ophthalmic preservatives as absorption promoters for ocular drug delivery. J Pharm Pharmacol. 1995;47:703-707.
41. Madhu C, Rix PJ, Shackleton MJ, Nguyen TG, Tang-Liu DD. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits. J Pharm Sci. 1996;85:415-418.
42. Ashton P, Diepold R, Platzer A, Lee VH. The effect of chlorhexidine acetate on the corneal penetration of sorbitol from an arnolol formulation in the albino rabbit. J Ocul Pharmacol. 1990;6:37-42.
43. Green K, Tonjum AM. The effect of benzalkonium chloride on the electropotential of the rabbit cornea. Acta Ophthalmol (Copenh). 1975;53:348-357.
44. Monti D, Chetoni P, Burgalassi S, Najarro M, Saettone MF. Increased corneal hydration induced by potential ocular penetration enhancers: assessment by differential scanning calorimetry (DSC) and by desiccation. Int J Pharm. 2002;232:139-147.
45. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94.
46. Rojanasakul Y, Liaw J, Robinson J. Mechanisms of action of some penetration enhancers in the cornea: Laser scanning confocal microscopic and electrophysiological studies. Int J Pharm. 1990; 66:131-142.
47. Green K, Johnson RE, Chapman JM, Nelson E, Cheeks L. Preservative effects on the healing rate of rabbit corneal epithelium. Lens Eye Toxic Res. 1989;6:37-41.
48. Fasano A, Baudry B, Pumplin DW, et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA. 1991;88:5242-5246.
49. Di Pierro M, Lu R, Uzzau S, et al. Zonula occludens toxin structurefunction analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem. 2001;276:19160-19165.
50. Cox DS, Raje S, Gao H, Salama NN, Eddington ND. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm Res. 2002;19:1680-1688.
51. Karyekar CS, Fasano A, Raje S, Lu R, Dowling TC, Eddington ND. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J Pharm Sci. 2003;92:414-423.
52. Salama NN, Fasano A, Thakar M, Eddington ND. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents. J Pharmacol Exp Ther. 2005;312:199-205.
53. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003;9: 711-715.
54. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002; 109:1709-1716.
55. Tourville E, Tardif Y. Intravitreal methotrexate injections for intraocular involvement in primary central nervous system lymphoma. Can J Ophthalmol. 2003;38:598-601.
56. Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11:131-139.
57. Joussen AM, Kruse FE, Volcker HE, Kirchhof B. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1999;237:920-927.
58. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528-532.